Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266600 | 1.00 | RAB9A (0.59) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL4256756 | 0.91 | CNR1 (0.54) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL4256768 | 0.91 | CNR1 (0.54) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL4265549 | 0.86 | MCHR1 (0.46) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL4265569 | 0.86 | MCHR1 (0.46) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL4263717 | 0.86 | SMYD3 (0.57) | RAB9ASMN1; SMN2MCHR1ADRA2AHRH1 | |
| SCHEMBL4263722 | 0.86 | SMYD3 (0.57) | RAB9ASMN1; SMN2MCHR1ADRA2AHRH1 | |
| SCHEMBL4257979 | 0.85 | MCHR1 (0.59) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL4257973 | 0.85 | MCHR1 (0.59) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6463248 | 0.83 | MCHR1 (0.81) | RAB9AHPGDSMN1; SMN2MCHR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | RAB9A 3025/4885HPGD 1732/4885SMN1; SMN2 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.